Clinical and pathologic features of patients with MDS, MDS/MPD, or AML positive for JAK2 V617F mutation
. | . | . | . | . | . | . | Bone marrow morphology . | . | . | . | . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WHO diagnosis . | Age . | Hgb, g/L . | Platelets, × 109/L . | MCV, fL . | ANC, ×109/L . | AMC, ×109/L . | Blasts, % . | Cellularity, % . | Megakaryocytes . | Megakaryocyte morphology . | Reticulin fibrosis . | RS, % . | Cytogenetics . | IPSS score . | Splenomegaly, Y/N . | JAK2 V617F mutation . | |||||
| RAEB-2 | 82 | 114 | 7 | 86.3 | 1.278 | 0.711 | 9* | 10 | Decreased | Dysplastic, small, hyposegmented | 3+ | 2 | NA—no growth 43-45,XX,del(5)(q13q33), -6,-10,-13,add(17) (p11.2),-20,+r, +1-3mar[cp7]/46,XX[13] | 1 | Y | G/T | |||||
| AML | 75 | 108 | 18 | 94.3 | 2.369 | 0.115 | 24 | 70 | Decreased | Normal | 2+ | 4 | 2 | N | G/T | ||||||
| CMML-1 | 79 | 113 | 309 | 94.7 | 6.170 | 1.199 | 0 | 85 | Increased and clustered | Large, complex hyperlobate nuclei | 2+ | 2 | 47,XY,+8[7]/46,XY[13] | 0.5 | N | G/T | |||||
| CMML-2 | 44 | 89 | 499 | 86.1 | 24.078 | 7.223 | 9† | 100 | Increased and clustered | Dysplastic | 3+ | 1 | 46,XY,t(8;9)(q22;p24)[20] | 1 | Y | G/T | |||||
| MDS/MPD-U§ | 79 | 96 | 122 | 90.9 | 4.328 | 0.108 | 0 | 30‡ | Increased and clustered | Dysplastic hyperchromatic nuclei | 4+‡ | 65 | 46,XX[20] | 0.5 | Y | G/T | |||||
| MDS/MPD-U§ | 71 | 83 | 413 | 89.8 | 6.578 | 0 | 7 | 30‡ | Increased, focally clustered | Dysplastic hyperchromatic nuclei | 4+‡ | 0 | 47,XY,+8[14] | 1 | Y | G/T | |||||
| MDS/MPD-U§ | 63 | 85 | 8 | 95.3 | 5.852 | 0.228 | 2 | 10 | Decreased | Dysplastic, hyperchromatic hyposegmented nuclei | 3+ | 0 | NA-no growth | 0.5 | Y | G/T | |||||
. | . | . | . | . | . | . | Bone marrow morphology . | . | . | . | . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WHO diagnosis . | Age . | Hgb, g/L . | Platelets, × 109/L . | MCV, fL . | ANC, ×109/L . | AMC, ×109/L . | Blasts, % . | Cellularity, % . | Megakaryocytes . | Megakaryocyte morphology . | Reticulin fibrosis . | RS, % . | Cytogenetics . | IPSS score . | Splenomegaly, Y/N . | JAK2 V617F mutation . | |||||
| RAEB-2 | 82 | 114 | 7 | 86.3 | 1.278 | 0.711 | 9* | 10 | Decreased | Dysplastic, small, hyposegmented | 3+ | 2 | NA—no growth 43-45,XX,del(5)(q13q33), -6,-10,-13,add(17) (p11.2),-20,+r, +1-3mar[cp7]/46,XX[13] | 1 | Y | G/T | |||||
| AML | 75 | 108 | 18 | 94.3 | 2.369 | 0.115 | 24 | 70 | Decreased | Normal | 2+ | 4 | 2 | N | G/T | ||||||
| CMML-1 | 79 | 113 | 309 | 94.7 | 6.170 | 1.199 | 0 | 85 | Increased and clustered | Large, complex hyperlobate nuclei | 2+ | 2 | 47,XY,+8[7]/46,XY[13] | 0.5 | N | G/T | |||||
| CMML-2 | 44 | 89 | 499 | 86.1 | 24.078 | 7.223 | 9† | 100 | Increased and clustered | Dysplastic | 3+ | 1 | 46,XY,t(8;9)(q22;p24)[20] | 1 | Y | G/T | |||||
| MDS/MPD-U§ | 79 | 96 | 122 | 90.9 | 4.328 | 0.108 | 0 | 30‡ | Increased and clustered | Dysplastic hyperchromatic nuclei | 4+‡ | 65 | 46,XX[20] | 0.5 | Y | G/T | |||||
| MDS/MPD-U§ | 71 | 83 | 413 | 89.8 | 6.578 | 0 | 7 | 30‡ | Increased, focally clustered | Dysplastic hyperchromatic nuclei | 4+‡ | 0 | 47,XY,+8[14] | 1 | Y | G/T | |||||
| MDS/MPD-U§ | 63 | 85 | 8 | 95.3 | 5.852 | 0.228 | 2 | 10 | Decreased | Dysplastic, hyperchromatic hyposegmented nuclei | 3+ | 0 | NA-no growth | 0.5 | Y | G/T | |||||
MDS indicates myelodysplastic syndrome; MDS/MPD, myelodysplastic/myeloproliferative disease; AML, acute myeloid leukemia; RAEB, refractory anemia with excess blasts; CMML, chronic myelomonocytic leukemia; MCV, mean cell volume; ANC, absolute neutrophil count; AMC, absolute monocyte count; RS, ringed sideroblasts; and NA, not available.
10% blasts in peripheral blood.
12% blasts in peripheral blood.
Extensive reticulin and collagenous stromal fibrosis.
Cases of MDS/MPD-U classified as RARS-T were excluded and presented in a separate table (Table 3).